Inactivated and subunit vaccines to prevent shigellosis

References

• Kotloff KL, Winickoff JP, Ivanoff B et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull. World Health Organ.77(8), 651–666 (1999).
   PubMed Web of Science ®Google Scholar
• Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nat. Rev. Microbiol.5(7), 540–553 (2007).
   PubMed Web of Science ®Google Scholar
• Venkatesan MM, Ranallo RT. Live-attenuated Shigella vaccines. Expert Rev. Vaccines5(5), 669–686 (2006).
   PubMed Web of Science ®Google Scholar
• DuPont HL, Levine MM, Hornick RB, Formal SB. Inoculum size in shigellosis and implications for expected mode of transmission. J. Infect. Dis.159(6), 1126–1128 (1989).
   PubMed Web of Science ®Google Scholar
• Molbak K, Jensen H, Ingholt L, Aaby P. Risk factors for diarrheal disease incidence in early childhood: a community cohort study from Guinea-Bissau. Am. J. Epidemiol.146(3), 273–282 (1997).
   PubMed Web of Science ®Google Scholar
• Guerrant DI, Moore SR, Lima AA, Patrick PD, Schorling JB, Guerrant RL. Association of early childhood diarrhea and cryptosporidiosis with impaired physical fitness and cognitive function four–seven years later in a poor urban community in northeast Brazil. Am. J. Trop. Med. Hyg.61(5), 707–713 (1999).
   PubMed Web of Science ®Google Scholar
• Niehaus MD, Moore SR, Patrick PD et al. Early childhood diarrhea is associated with diminished cognitive function 4 to 7 years later in children in a northeast Brazilian shantytown. Am. J. Trop. Med. Hyg.66(5), 590–593 (2002).
   PubMed Web of Science ®Google Scholar
• Watarai M, Funato S, Sasakawa C. Interaction of Ipa proteins of Shigella flexneri with a5b1 integrin promotes entry of the bacteria into mammalian cells. J. Exp. Med.183(3), 991–999 (1996).
   PubMed Web of Science ®Google Scholar
• Tyrer P, Foxwell AR, Cripps AW, Apicella MA, Kyd JM. Microbial pattern recognition receptors mediate M-cell uptake of a Gram-negative bacterium. Infect. Immun.74(1), 625–631 (2006).
   PubMed Web of Science ®Google Scholar
• Zychlinsky A, Prevost MC, Sansonetti PJ. Shigella flexneri induces apoptosis in infected macrophages. Nature358(6382), 167–169 (1992).
   PubMed Web of Science ®Google Scholar
• Zychlinsky A, Kenny B, Menard R, Prevost MC, Holland IB, Sansonetti PJ. IpaB mediates macrophage apoptosis induced by Shigella flexneri.Mol. Microbiol.11(4), 619–627 (1994).
   PubMed Web of Science ®Google Scholar
• Hilbi H, Zychlinsky A, Sansonetti PJ. Macrophage apoptosis in microbial infections. Parasitology115(Suppl.), S79–S87 (1997).
   Google Scholar
• Hilbi H, Moss JE, Hersh D et al.Shigella-induced apoptosis is dependent on caspase-1 which binds to IpaB. J. Biol. Chem.273(49), 32895–32900 (1998).
   PubMed Web of Science ®Google Scholar
• Edgeworth JD, Spencer J, Phalipon A, Griffin GE, Sansonetti PJ. Cytotoxicity and interleukin-1b processing following Shigella flexneri infection of human monocyte-derived dendritic cells. Eur. J. Immunol.32(5), 1464–1471 (2002).
   PubMed Web of Science ®Google Scholar
• Hathaway LJ, Griffin GE, Sansonetti PJ, Edgeworth JD. Human monocytes kill Shigella flexneri but then die by apoptosis associated with suppression of proinflammatory cytokine production. Infect. Immun.70(7), 3833–3842 (2002).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Nakanishi K, Tsutsui H et al. A novel caspase-1/Toll-like receptor 4-independent pathway of cell death induced by cytosolic Shigella in infected macrophages. J. Biol. Chem.280(14), 14042–14050 (2005).
   PubMed Web of Science ®Google Scholar
• Schroeder GN, Jann NJ, Hilbi H. Intracellular type III secretion by cytoplasmic Shigella flexneri promotes caspase-1-dependent macrophage cell death. Microbiology153(Pt 9), 2862–2876 (2007).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Franchi L, Toma C et al. Differential regulation of caspase-1 activation, pyroptosis, and autophagy via Ipaf and ASC in Shigella-infected macrophages. PLoS Pathog.3(8), e111 (2007).
   PubMed Web of Science ®Google Scholar
• Schroeder GN, Hilbi H. Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. Clin. Microbiol. Rev.21(1), 134–156 (2008).
   PubMed Web of Science ®Google Scholar
• Rallabhandi P, Awomoyi A, Thomas KE et al. Differential activation of human TLR4 by Escherichia coli and Shigella flexneri 2a lipopolysaccharide: combined effects of lipid A acylation state and TLR4 polymorphisms on signaling. J. Immunol.180(2), 1139–1147 (2008).
   PubMed Web of Science ®Google Scholar
• Tamano K, Aizawa S, Katayama E et al. Supramolecular structure of the Shigella type III secretion machinery: the needle part is changeable in length and essential for delivery of effectors. EMBO J.19(15), 3876–3887 (2000).
   PubMed Web of Science ®Google Scholar
• Espina M, Olive AJ, Kenjale R et al. IpaD localizes to the tip of the type III secretion system needle of Shigella flexneri. Infect. Immun.74(8), 4391–4400 (2006).
   PubMed Web of Science ®Google Scholar
• Stensrud KF, Adam PR, La Mar CD et al. Deoxycholate interacts with IpaD of Shigella flexneri in inducing the recruitment of IpaB to the type III secretion apparatus needle tip. J. Biol. Chem.283(27), 18646–18654 (2008).
   PubMed Web of Science ®Google Scholar
• Epler CR, Dickenson NE, Olive AJ, Picking WL, Picking WD. Liposomes recruit IpaC to the Shigella flexneri type III secretion apparatus needle as a final step in secretion induction. Infect. Immun.77(7), 2754–2761 (2009).
   PubMed Web of Science ®Google Scholar
• West NP, Sansonetti P, Mounier J et al. Optimization of virulence functions through glucosylation of Shigella LPS. Science307(5713), 1313–1317 (2005).
   PubMed Web of Science ®Google Scholar
• Blocker A, Gounon P, Larquet E et al. The tripartite type III secreton of Shigella flexneri inserts IpaB and IpaC into host membranes. J. Cell Biol.147(3), 683–693 (1999).
   PubMed Web of Science ®Google Scholar
• High N, Mounier J, Prevost MC, Sansonetti PJ. IpaB of Shigella flexneri causes entry into epithelial cells and escape from the phagocytic vacuole. EMBO J.11(5), 1991–1999 (1992).
   PubMed Web of Science ®Google Scholar
• Barzu S, Benjelloun-Touimi Z, Phalipon A, Sansonetti P, Parsot C. Functional analysis of the Shigella flexneri IpaC invasin by insertional mutagenesis. Infect. Immun.65(5), 1599–1605 (1997).
   PubMed Web of Science ®Google Scholar
• Suzuki T, Nunez G. A role for Nod-like receptors in autophagy induced by Shigella infection. Autophagy4(1), 73–75 (2008).
   PubMed Web of Science ®Google Scholar
• Sansonetti PJ, Arondel J, Huerre M, Harada A, Matsushima K. Interleukin-8 controls bacterial transepithelial translocation at the cost of epithelial destruction in experimental shigellosis. Infect. Immun.67(3), 1471–1480 (1999).
   PubMed Web of Science ®Google Scholar
• Raqib R, Lindberg AA, Wretlind B, Bardhan PK, Andersson U, Andersson J. Persistence of local cytokine production in shigellosis in acute and convalescent stages. Infect. Immun.63(1), 289–296 (1995).
   PubMed Web of Science ®Google Scholar
• Okuda J, Toyotome T, Kataoka N et al.Shigella effector IpaH9.8 binds to a splicing factor U2AF(35) to modulate host immune responses. Biochem. Biophys. Res. Commun.333(2), 531–539 (2005).
   PubMed Web of Science ®Google Scholar
• Ingersoll MA, Zychlinsky A. ShiA abrogates the innate T-cell response to Shigella flexneri infection. Infect. Immun.74(4), 2317–2327 (2006).
   PubMed Web of Science ®Google Scholar
• Ingersoll MA, Moss JE, Weinrauch Y, Fisher PE, Groisman EA, Zychlinsky A. The ShiA protein encoded by the Shigella flexneri SHI-2 pathogenicity island attenuates inflammation. Cell Microbiol.5(11), 797–807 (2003).
   PubMed Web of Science ®Google Scholar
• Zurawski DV, Mumy KL, Faherty CS, McCormick BA, Maurelli AT. Shigella flexneri type III secretion system effectors OspB and OspF target the nucleus to downregulate the host inflammatory response via interactions with retinoblastoma protein. Mol. Microbiol.71(2), 350–368 (2009).
   PubMed Web of Science ®Google Scholar
• Kim DW, Lenzen G, Page AL, Legrain P, Sansonetti PJ, Parsot C. The Shigella flexneri effector OspG interferes with innate immune responses by targeting ubiquitin-conjugating enzymes. Proc. Natl Acad. Sci. USA102(39), 14046–14051 (2005).
   PubMed Web of Science ®Google Scholar
• Le-Barillec K, Magalhaes JG, Corcuff E et al. Roles for T and NK cells in the innate immune response to Shigella flexneri.J. Immunol.175(3), 1735–1740 (2005).
   PubMed Web of Science ®Google Scholar
• Ferreccio C, Prado V, Ojeda A et al. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Am. J. Epidemiol.134(6), 614–627 (1991).
   PubMed Web of Science ®Google Scholar
• Islam D, Wretlind B, Hammarstrom L, Christensson B, Lindberg AA. Semiquantitative estimation of Shigella antigen-specific antibodies: correlation with disease severity during shigellosis. APMIS104(7–8), 563–574 (1996).
   PubMed Web of Science ®Google Scholar
• Andrews GP, Hromockyj AE, Coker C, Maurelli AT. Two novel virulence loci, mxiA and mxiB, in Shigella flexneri 2a facilitate excretion of invasion plasmid antigens. Infect. Immun.59(6), 1997–2005 (1991).
   PubMed Web of Science ®Google Scholar
• Islam D, Bardhan PK, Lindberg AA, Christensson B. Shigella infection induces cellular activation of T and B cells and distinct species-related changes in peripheral blood lymphocyte subsets during the course of the disease. Infect. Immun.63(8), 2941–2949 (1995).
   PubMed Web of Science ®Google Scholar
• Runyen-Janecky LJ, Payne SM. Identification of chromosomal Shigella flexneri genes induced by the eukaryotic intracellular environment. Infect. Immun.70(8), 4379–4388 (2002).
   PubMed Web of Science ®Google Scholar
• Purdy GE, Fisher CR, Payne SM. IcsA surface presentation in Shigella flexneri requires the periplasmic chaperones DegP, Skp, and SurA. J. Bacteriol.189(15), 5566–5573 (2007).
   PubMed Web of Science ®Google Scholar
• Fasano A, Noriega FR, Maneval DR Jr. et al.Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro. J. Clin. Invest.95(6), 2853–2861 (1995).
   PubMed Web of Science ®Google Scholar
• Fasano A, Noriega FR, Liao FM, Wang W, Levine MM. Effect of Shigella enterotoxin 1 (ShET1) on rabbit intestine in vitro and in vivo. Gut40(4), 505–511 (1997).
   PubMed Web of Science ®Google Scholar
• Oaks EV, Hale TL, Formal SB. Serum immune response to Shigella protein antigens in rhesus monkeys and humans infected with Shigella spp. Infect. Immun.53(1), 57–63 (1986).
   PubMed Web of Science ®Google Scholar
• Raqib R, Qadri F, SarkEr P et al. Delayed and reduced adaptive humoral immune responses in children with shigellosis compared with in adults. Scand. J. Immunol.55(4), 414–423 (2002).
   PubMed Web of Science ®Google Scholar
• Coster TS, Hoge CW, VanDeVerg LL et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect. Immun.67(7), 3437–3443 (1999).
   PubMed Web of Science ®Google Scholar
• Orr N, Robin G, Lowell G, Cohen D. Presence of specific immunoglobulin A-secreting cells in peripheral blood after natural infection with Shigella sonnei. J. Clin. Microbiol.30(8), 2165–2168 (1992).
   PubMed Web of Science ®Google Scholar
• Li A, Rong ZC, Ekwall E, Forsum U, Lindberg AA. Serum antibody responses against Shigella lipopolysaccharides and invasion plasmid-coded antigens in Shigella infected Swedish patients. Scand. J. Infect. Dis.25(5), 569–577 (1993).
   PubMed Web of Science ®Google Scholar
• Chowers Y, Kirschner J, Keller N et al. O-specific [corrected] polysaccharide conjugate vaccine-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative. Proc. Natl Acad. Sci. USA104(7), 2396–2401 (2007).
   PubMed Web of Science ®Google Scholar
• Mills JA, Buysse JM, Oaks EV. Shigella flexneri invasion plasmid antigens B and C: epitope location and characterization with monoclonal antibodies. Infect. Immun.56(11), 2933–2941 (1988).
   PubMed Web of Science ®Google Scholar
• Sani M, Allaoui A, Fusetti F, Oostergetel GT, Keegstra W, Boekema EJ. Structural organization of the needle complex of the type III secretion apparatus of Shigella flexneri. Micron38(3), 291–301 (2007).
   PubMed Web of Science ®Google Scholar
• Lowell GH, MacDermott RP, Summers PL, Reeder AA, Bertovich MJ, Formal SB. Antibody-dependent cell-mediated antibacterial activity: K lymphocytes, monocytes, and granulocytes are effective against Shigella. J. Immunol.125(6), 2778–2784 (1980).
   PubMed Web of Science ®Google Scholar
• Cleary TG, Winsor DK, Reich D, Ruiz-Palacios G, Calva JJ. Human milk immunoglobulin A antibodies to Shigella virulence determinants. Infect. Immun.57(6), 1675–1679 (1989).
   PubMed Web of Science ®Google Scholar
• Cohen D, Orr N, Robin G et al. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination. Clin. Diagn. Lab. Immunol.3(4), 451–455 (1996).
   PubMedGoogle Scholar
• Islam D, Wretlind B, Ryd M, Lindberg AA, Christensson B. Immunoglobulin subclass distribution and dynamics of Shigella-specific antibody responses in serum and stool samples in shigellosis. Infect. Immun.63(5), 2054–2061 (1995).
   PubMed Web of Science ®Google Scholar
• Schultsz C, Qadri F, Hossain SA, Ahmed F, Ciznar I. Shigella-specific IgA in saliva of children with bacillary dysentery. FEMS Microbiol. Immunol.4(2), 65–72 (1992).
   PubMedGoogle Scholar
• Islam D, Veress B, Bardhan PK, Lindberg AA, Christensson B. In situ characterization of inflammatory responses in the rectal mucosae of patients with shigellosis. Infect. Immun.65(2), 739–749 (1997).
   PubMed Web of Science ®Google Scholar
• Robbins JB, Chu C, Schneerson R. Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and Shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides. Clin. Infect. Dis.15(2), 346–361 (1992).
   PubMed Web of Science ®Google Scholar
• Ashkenazi S, Passwell JH, Harlev E et al. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children. J. Infect. Dis.179(6), 1565–1568 (1999).
   PubMed Web of Science ®Google Scholar
• Robbins JB, Schneerson R. Future vaccine development at NICHD. Ann NY Acad. Sci.1038, 49–59 (2004).
   PubMed Web of Science ®Google Scholar
• Oberhelman RA, Kopecko DJ, Salazar-Lindo E et al. Prospective study of systemic and mucosal immune responses in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharides. Infect. Immun.59(7), 2341–2350 (1991).
   PubMed Web of Science ®Google Scholar
• Hayani KC, Guerrero ML, Morrow AL et al. Concentration of milk secretory immunoglobulin A against Shigella virulence plasmid-associated antigens as a predictor of symptom status in Shigella-infected breast-fed infants. J. Pediatr.121(6), 852–856 (1992).
   PubMed Web of Science ®Google Scholar
• Tacket CO, Binion SB, Bostwick E, Losonsky G, Roy MJ, Edelman R. Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge. Am. J. Trop. Med. Hyg.47(3), 276–283 (1992).
   PubMed Web of Science ®Google Scholar
• Formal SB, Oaks EV, Olsen RE, Wingfield-Eggleston M, Snoy PJ, Cogan JP. Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei. J. Infect. Dis.164(3), 533–537 (1991).
   PubMed Web of Science ®Google Scholar
• Noriega FR, Liao FM, Maneval DR, Ren S, Formal SB, Levine MM. Strategy for cross-protection among Shigella flexneri serotypes. Infect. Immun.67(2), 782–788 (1999).
   PubMed Web of Science ®Google Scholar
• Turbyfill KR, Joseph SW, Oaks EV. Recognition of three epitopic regions on invasion plasmid antigen C by immune sera of rhesus monkeys infected with Shigella flexneri 2a. Infect. Immun.63(10), 3927–3935 (1995).
   PubMed Web of Science ®Google Scholar
• Kweon MN. Shigellosis: the current status of vaccine development. Curr. Opin. Infect. Dis.21(3), 313–318 (2008).
   PubMed Web of Science ®Google Scholar
• Trofa AF, Ueno-Olsen H, Oiwa R, Yoshikawa M. Dr. Kiyoshi Shiga: discoverer of the dysentery bacillus. Clin. Infect. Dis.29(5), 1303–1306 (1999).
   PubMed Web of Science ®Google Scholar
• Osorio M, Bray MD, Walker RI. Vaccine potential for inactivated Shigellae. Vaccine25(9), 1581–1592 (2007).
   PubMed Web of Science ®Google Scholar
• McKenzie R, Walker RI, Nabors GS et al. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial. Vaccine24(18), 3735–3745 (2006).
   PubMed Web of Science ®Google Scholar
• Mukhopadhaya A, Mahalanabis D, Khanam J, Chakrabarti MK. Protective efficacy of oral immunization with heat-killed Shigella flexneri 2a in animal model: study of cross protection, immune response and antigenic recognition. Vaccine21(21–22), 3043–3050 (2003).
   Google Scholar
• Chakrabarti MK, Bhattacharya J, Bhattacharya MK, Nair GB, Bhattacharya SK, Mahalanabis D. Killed oral Shigella vaccine made from Shigella flexneri 2a protects against challenge in the rabbit model of shigellosis. Acta Paediatr.88(2), 161–165 (1999).
   PubMed Web of Science ®Google Scholar
• Formal SB, Labrec EH, Palmer A, Falkow S. Protection of monkeys against experimental shigellosis with attenuated vaccines. J. Bacteriol.90(1), 63–68 (1965).
   PubMed Web of Science ®Google Scholar
• Tabrizi CA, Walcher P, Mayr UB et al. Bacterial ghosts – biological particles as delivery systems for antigens, nucleic acids and drugs. Curr. Opin. Biotechnol.15(6), 530–537 (2004).
   PubMed Web of Science ®Google Scholar
• Higgins AR, Floyd TM, Kader MA. Studies in shigellosis. III. A controlled evaluation of a monovalent Shigella vaccine in a highly endemic environment. Am. J. Trop. Med. Hyg.4(2), 281–288 (1955).
   PubMed Web of Science ®Google Scholar
• Formal SB, LaBrec EH, Kent TH, May HC, Lowenthal JP, Berman S. Biological properties of freeze-dried attenuated Shigella vaccines. Proc. Soc. Exp. Biol. Med.124(1), 284–289 (1967).
   PubMed Web of Science ®Google Scholar
• Shaughnessy HJ, OLsson RC, Bass K, Friewer F, Levinson SO. Experimental human bacillary dysentery: polyvalent dysentery vaccine in its prevention. J. Am. Med. Assoc.132(7), 362–371 (1946).
   PubMed Web of Science ®Google Scholar
• Hartman AB, Van De Verg LL, Venkatesan MM. Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines. Infect. Immun.67(11), 5841–5847 (1999).
   PubMed Web of Science ®Google Scholar
• Pope LM, Reed KE, Payne SM. Increased protein secretion and adherence to HeLa cells by Shigella spp. following growth in the presence of bile salts. Infect. Immun.63(9), 3642–3648 (1995).
   PubMed Web of Science ®Google Scholar
• Payne SM. Iron and virulence in Shigella. Mol. Microbiol.3(9), 1301–1306 (1989).
   PubMed Web of Science ®Google Scholar
• Sen A, Leon MA, Palchaudhuri S. Environmental signals induce major changes in virulence of Shigella spp. FEMS Microbiol. Lett.68(2), 231–236 (1991).
   PubMed Web of Science ®Google Scholar
• Boulette ML, Payne SM. Anaerobic regulation of Shigella flexneri virulence: ArcA regulates Fur and iron acquisition genes. J. Bacteriol.189(19), 6957–6967 (2007).
   PubMed Web of Science ®Google Scholar
• Black RE, Levine MM, Clements ML, Young CR, Svennerholm AM, Holmgren J. Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect. Immun.55(5), 1116–1120 (1987).
   PubMed Web of Science ®Google Scholar
• Trach DD, Clemens JD, Ke NT et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet349(9047), 231–235 (1997).
   PubMed Web of Science ®Google Scholar
• Walker RI. Considerations for development of whole cell bacterial vaccines to prevent diarrheal diseases in children in developing countries. Vaccine23(26), 3369–3385 (2005).
   PubMed Web of Science ®Google Scholar
• Taylor DN, Trofa AC, Sadoff J et al. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infect. Immun.61(9), 3678–3687 (1993).
   PubMed Web of Science ®Google Scholar
• Pavliakova D, Chu C, Bystricky S et al. Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide–protein conjugates in mice. Infect. Immun.67(10), 5526–5529 (1999).
   PubMed Web of Science ®Google Scholar
• Passwell JH, Harlev E, Ashkenazi S et al. Safety and immunogenicity of improved Shigella O-specific polysaccharide–protein conjugate vaccines in adults in Israel. Infect. Immun.69(3), 1351–1357 (2001).
   PubMed Web of Science ®Google Scholar
• Cohen D, Ashkenazi S, Green MS et al. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet349(9046), 155–159 (1997).
   PubMed Web of Science ®Google Scholar
• Wright K, Guerreiro C, Laurent I, Baleux F, Mulard LA. Preparation of synthetic glycoconjugates as potential vaccines against Shigella flexneri serotype 2a disease. Org. Biomol. Chem.2(10), 1518–1527 (2004).
   PubMed Web of Science ®Google Scholar
• Pavliakova D, Moncrief JS, Lyerly DM et al.Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice. Infect. Immun.68(4), 2161–2166 (2000).
   PubMed Web of Science ®Google Scholar
• Robbins JB, Schneerson R. Evaluating the Haemophilus influenzae type b conjugate vaccine PRP-D. N. Engl. J. Med.323(20), 1415–1416 (1990).
   PubMed Web of Science ®Google Scholar
• Anderson PW Jr, Stein EC, Insel RA. Background and indications for Haemophilus influenzae type b vaccines consisting of capsular antigen coupled to protein carriers. Contrib. Microbiol. Immunol.10, 115–124 (1989).
   PubMedGoogle Scholar
• Szu SC, Li XR, Schneerson R, Vickers JH, Bryla D, Robbins JB. Comparative immunogenicities of Vi polysaccharide–protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi. Infect. Immun.57(12), 3823–3827 (1989).
   PubMed Web of Science ®Google Scholar
• Pozsgay V, Kubler-Kielb J, Schneerson R, Robbins JB. Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice. Proc. Natl Acad. Sci. USA104(36), 14478–14482 (2007).
   PubMed Web of Science ®Google Scholar
• Phalipon A, Mulard LA, Sansonetti PJ. Vaccination against shigellosis: is it the path that is difficult or is it the difficult that is the path? Microbes Infect.10(9), 1057–1062 (2008).
   PubMed Web of Science ®Google Scholar
• Chu CY, Liu BK, Watson D et al. Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga’s bacillus) bound to tetanus toxoid. Infect. Immun.59(12), 4450–4458 (1991).
   PubMed Web of Science ®Google Scholar
• Kopecko DJ, Washington O, Formal SB. Genetic and physical evidence for plasmid control of Shigella sonnei form I cell surface antigen. Infect. Immun.29(1), 207–214 (1980).
   PubMed Web of Science ®Google Scholar
• Kubler-Kielb J, Schneerson R, Mocca C, Vinogradov E. The elucidation of the structure of the core part of the LPS from Plesiomonas shigelloides serotype O17 expressing O-polysaccharide chain identical to the Shigella sonnei O-chain. Carbohydr. Res.343(18), 3123–3127 (2008).
   PubMed Web of Science ®Google Scholar
• Pozsgay V, Chu C, Pannell L, Wolfe J, Robbins JB, Schneerson R. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proc. Natl Acad. Sci. USA96(9), 5194–5197 (1999).
   PubMed Web of Science ®Google Scholar
• Robbins JB, Kubler-Kielb J, Vinogradov E et al. Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core–protein conjugates. Proc. Natl Acad. Sci. USA106(19), 7974–7978 (2009).
   PubMed Web of Science ®Google Scholar
• Ahmed A, Li J, Shiloach Y, Robbins JB, Szu SC. Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2–5-year-old children. J. Infect. Dis.193(4), 515–521 (2006).
   PubMed Web of Science ®Google Scholar
• Cohen D, Ashkenazi S, Green M et al. Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. Infect. Immun.64(10), 4074–4077 (1996).
   PubMed Web of Science ®Google Scholar
• Passwell JH, Ashkenazi S, Harlev E et al. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a–rEPAsucc conjugate vaccines in one- to four-year-old children. Pediatr. Infect. Dis. J.22(8), 701–706 (2003).
   PubMed Web of Science ®Google Scholar
• Klein Klouwenberg P, Bont L. Neonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines. Clin. Dev. Immunol.2008, 628963 (2008).
   PubMedGoogle Scholar
• Acosta CJ, Galindo CM, Deen JL et al. Vaccines against cholera, typhoid fever and shigellosis for developing countries. Expert Opin. Biol. Ther.4(12), 1939–1951 (2004).
   PubMed Web of Science ®Google Scholar
• Phalipon A, Costachel C, Grandjean C et al. Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: implications for the development of a chemically defined glycoconjugate vaccine. J. Immunol.176(3), 1686–1694 (2006).
   PubMed Web of Science ®Google Scholar
• Robbins JB, Kubler-Kielb J, Vinogradov E et al. Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core–protein conjugates. Proc. Natl Acad. Sci. USA106(19), 7974–7978 (2009).
   PubMed Web of Science ®Google Scholar
• Phalipon A, Tanguy M, Grandjean C et al. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection. J. Immunol.182(4), 2241–2247 (2009).
   PubMed Web of Science ®Google Scholar
• Phalipon A, Folgori A, Arondel J et al. Induction of anti-carbohydrate antibodies by phage library-selected peptide mimics. Eur. J. Immunol.27(10), 2620–2625 (1997).
   PubMed Web of Science ®Google Scholar
• Borrelli S, Hossany RB, Pinto BM. Immunological evidence for functional rather than structural mimicry by a Shigella flexneri Y polysaccharide-mimetic peptide. Clin. Vaccine Immunol.15(7), 1106–1114 (2008).
   PubMed Web of Science ®Google Scholar
• Clement MJ, Fortune A, Phalipon A et al. Toward a better understanding of the basis of the molecular mimicry of polysaccharide antigens by peptides: the example of Shigella flexneri 5a. J. Biol. Chem.281(4), 2317–2332 (2006).
   PubMed Web of Science ®Google Scholar
• Levenson VI, Chernokhvostova EV, Lyubinskaya MM, Salamatova SA, Dzhikidze EK, Stasilevitch ZK. Parenteral immunization with Shigella ribosomal vaccine elicits local IgA response and primes for mucosal memory. Int. Arch. Allergy Appl. Immunol.87(1), 25–31 (1988).
   PubMedGoogle Scholar
• Lieberman MM, McKissock DC, Wright GL. Passive immunization against Pseudomonas with a ribosomal vaccine-induced immune serum and immunoglobulin fractions. Infect. Immun.23(2), 509–521 (1979).
   PubMed Web of Science ®Google Scholar
• Angerman CR, Eisenstein TK. Comparative efficacy and toxicity of a ribosomal vaccine, acetone-killed cells, lipopolysaccharide, and a live cell vaccine prepared from Salmonella typhhimurium. Infect. Immun.19(2), 575–582 (1978).
   PubMed Web of Science ®Google Scholar
• Chernokhvostova EV, Lyubinskaya MM, Belkin ZP, Levenson VI. Protective milk O antibodies induced in guinea pigs by parenteral Shigella ribosomal vaccine. Int. Arch. Allergy Appl. Immunol.92(3), 265–267 (1990).
   PubMedGoogle Scholar
• Levenson VI, Egorova TP, Belkin ZP et al. Protective ribosomal preparation from Shigella sonnei as a parenteral candidate vaccine. Infect. Immun.59(10), 3610–3618 (1991).
   PubMed Web of Science ®Google Scholar
• Levenson VI, Dzhikidze EK, Stasilevich ZK, Kavtaradze KN, Subbotina Iu L. Trial of the protective activity of ribosomal Sonne vaccine in monkeys. Vestn. Akad. Med. Nauk. SSSR3, 69–72 (1986).
   Google Scholar
• Levenson VJ, Mallett CP, Hale TL. Protection against local Shigella sonnei infection in mice by parenteral immunization with a nucleoprotein subcellular vaccine. Infect. Immun.63(7), 2762–2765 (1995).
   PubMed Web of Science ®Google Scholar
• Shim DH, Chang SY, Park SM et al. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a. Vaccine25(25), 4828–4836 (2007).
   PubMed Web of Science ®Google Scholar
• Orr N, Robin G, Cohen D, Arnon R, Lowell GH. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome–lipopolysaccharide vaccines in animal models. Infect. Immun.61(6), 2390–2395 (1993).
   PubMed Web of Science ®Google Scholar
• Orr N, Arnon R, Rubin G, Cohen D, Bercovier H, Lowell GH. Enhancement of anti-Shigella lipopolysaccharide (LPS) response by addition of the cholera toxin B subunit to oral and intranasal proteosome–Shigella flexneri2a LPS vaccines. Infect. Immun.62(11), 5198–5200 (1994).
   PubMed Web of Science ®Google Scholar
• Mallett CP, Hale TL, Kaminski RW et al. Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection. Infect. Immun.63(6), 2382–2386 (1995).
   PubMed Web of Science ®Google Scholar
• Fries LF, Montemarano AD, Mallett CP, Taylor DN, Hale TL, Lowell GH. Safety and immunogenicity of a proteosome–Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults. Infect. Immun.69(7), 4545–4553 (2001).
   PubMed Web of Science ®Google Scholar
• Turbyfill KR, Hartman AB, Oaks EV. Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine. Infect. Immun.68(12), 6624–6632 (2000).
   PubMed Web of Science ®Google Scholar
• Kaminski RW, Turbyfill KR, Oaks EV. Mucosal adjuvant properties of the Shigella invasin complex. Infect. Immun.74(5), 2856–2866 (2006).
   PubMed Web of Science ®Google Scholar
• Oaks EV, Turbyfill KR. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine. Vaccine24(13), 2290–2301 (2006).
   PubMed Web of Science ®Google Scholar
• Kaminski RW, Riddle MS, Williams C et al. Dose-finding, safety, and immunogenicity Phase 1 trial of an intranasal Shigella flexneri 2a Invaplex 50 vaccine in North American, adult volunteers. In: Eleventh Annual Conference on Vaccine Research. National Foundation for Infectious Diseases, Baltimore, MD, USA, 79 (2008).
   Google Scholar
• Turbyfill KR, Kaminski RW, Oaks EV. Immunogenicity and efficacy of highly purified invasin complex vaccine from Shigella flexneri 2a. Vaccine26(10), 1353–1364 (2008).
   PubMed Web of Science ®Google Scholar
• Kaminski RW, Turbyfill KR, Chao C, Ching WM, Oaks EV. Mucosal adjuvanticity of a Shigella invasin complex with DNA-based vaccines. Clin. Vaccine Immunol.16(4), 574–586 (2009).
   PubMedGoogle Scholar